Novel treatment strategies for aggressive non-Hodgkin's lymphoma

被引：5

作者：

Fayad, L ^{[1
]}

Younes, A ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 06期

关键词：

Akt; aurora; BAFF; CD40; Hsp-90; HDAC; mTOR; PLK; TRAIL;

D O I：

10.1517/14656566.7.6.733

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The World Health Organization has included different types of lymphoma under the aggressive category. In the US, diffuse large B-cell lymphoma is the most common aggressive lymphoma and accounts for > 30% of the 55,000 new cases diagnosed annually. Recent advances in the knowledge of the molecular biology have provided an increased understanding of the heterogeneity of non-Hodgkin's lymphoma. New treatments, especially those with the use of monoclonal antibodies, are improving both the survival and the response rate.

引用

页码：733 / 748

页数：16

共 50 条

[41] Novel and emerging treatment strategies for lupus nephritis [J].

Yap, Desmond Yat Hin ;

Mok, Chi Chiu .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (11) :1283-1292

[42] Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers [J].

Lineham, Ella ;

Spencer, John ;

Morley, Simon J. .

FUTURE MEDICINAL CHEMISTRY, 2017, 9 (13) :1539-1555

[43] Novel Therapeutic Strategies in Primary Sjogren's Syndrome [J].

Alunno, Alessia ;

Carubbi, Francesco ;

Bistoni, Onelia ;

Bartoloni, Elena ;

Valentini, Valentina ;

Gerli, Roberto .

ISRAEL MEDICAL ASSOCIATION JOURNAL, 2017, 19 (09) :576-580

[44] Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation [J].

Chapuy, Bjoern ;

Schuelper, Nikolai ;

Panse, Melanie ;

Dohm, Andrea ;

Hand, Elisabeth ;

Schroers, Roland ;

Truemper, Lorenz ;

Wulf, Gerald G. .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (04) :401-412

[45] Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines [J].

Maria Cosenza ;

Monica Civallero ;

Giulia Grisendi ;

Luigi Marcheselli ;

Erika Roat ;

Alessia Bari ;

Stefano Sacchi .

Annals of Hematology, 2012, 91 :1613-1622

[46] Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines [J].

Cosenza, Maria ;

Civallero, Monica ;

Grisendi, Giulia ;

Marcheselli, Luigi ;

Roat, Erika ;

Bari, Alessia ;

Sacchi, Stefano .

ANNALS OF HEMATOLOGY, 2012, 91 (10) :1613-1622

[47] PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas [J].

Chen, Deyu ;

Mao, Chaoming ;

Zhou, Yuepeng ;

Su, Yuting ;

Liu, Shenzha ;

Qi, Wen-Qing .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (01) :253-260

[48] Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin's Disease [J].

Lueke, Florian ;

Harrer, Dennis C. ;

Menhart, Karin ;

Wolff, Daniel ;

Holler, Ernst ;

Hellwig, Dirk ;

Herr, Wolfgang ;

Grube, Matthias ;

Vogelhuber, Martin ;

Reichle, Albrecht ;

Heudobler, Daniel .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[49] Malignant lymphoma in primary Sjogren's syndrome: An update on the pathogenesis and treatment [J].

Routsias, John G. ;

Goules, John D. ;

Charalampakis, Georgios ;

Tzima, Sotiria ;

Papageorgiou, Aristea ;

Voulgarelis, Michael .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2013, 43 (02) :178-186

[50] Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin [J].

Babcock, Justin T. ;

Quilliam, Lawrence A. .

CURRENT DRUG TARGETS, 2011, 12 (08) :1223-1231

← 1 2 3 4 5 →